Emergent Biosolutions (EBS) AI Stock Analysis

• Market Cap: $436.95M
• Dividend Yield: N/A
• Average Volume (3M): 889.21K
• Price to Earnings (P/E): 12.6
• Beta (1Y): 3.06
• Revenue Growth: -29.91%
• EPS Growth: N/A
• Country: US
• Employees: 900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.43
• Shares Outstanding: 51,770,860
• 10 Day Avg. Volume: 1,419,811
• 30 Day Avg. Volume: 889,213
• PEG Ratio: -0.10
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 0.89
• P/FCF Ratio: 4.22
• Enterprise Value/Market Cap: 1.85
• Enterprise Value/Revenue: 1.09
• Enterprise Value/Gross Profit: 2.24
• Enterprise Value/Ebitda: 3.40
• 1Y Price Target: $15.00
• Price Target Upside: 77.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.45
• Revenue Forecast (FY): $1.16B

• Rating: 53 Neutral
• Price Target: $9.00 ▲(6.64% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score reflects improving fundamentals (profitability and strong 2025 free cash flow) and constructive guidance, tempered by high historical volatility in results and still-elevated leverage. Technicals are the largest near-term drag, with bearish trend signals and very weak RSI.

Positive Factors

Cash generation recovery

Emergent delivered materially positive operating cash flow and FCF in 2025 after prior years of burn, converting nearly 0.9x of net income to FCF. Durable cash generation supports debt paydowns, targeted buybacks, and reinvestment in manufacturing and product programs, improving financial optionality over the medium term.

Deleveraging and liquidity

Management has proactively reduced gross debt (major prepayments, $100M voluntary payoff) and maintains significant liquidity and an undrawn revolver. Lower net leverage and available capacity reduce refinancing and covenant risk, giving the company more flexibility to execute its multi‑year transformation and invest in growth areas.

Manufacturing/Regulatory strength

FDA approval of the Winnipeg site for raxibacumab strengthens Emergent's regulated manufacturing footprint and supports its role as a supplier of medical countermeasures. Regulatory clearance enhances credibility for government contracts and CDMO partnerships, underpinning durable revenue from long‑term supply agreements.

Negative Factors

Multi‑year revenue decline

Top‑line has contracted materially over several years due to portfolio changes and lower procurement volumes. Reduced scale can erode operating leverage, make fixed costs a higher share of expenses, and limit the company's ability to absorb demand swings, challenging sustainable margin expansion absent new contract wins.

Elevated leverage remains

Although debt has declined, total debt remains modestly above equity and leverage is elevated relative to pre‑downturn levels. This structural leverage profile constrains capital allocation flexibility, increases interest expense sensitivity, and raises risk if operating cash flow weakens or contract timing shifts.

Customer concentration & revenue lumpy

A significant portion of revenue relies on government procurement and stockpiling, which are timing‑dependent and budget‑driven. That structural concentration leads to lumpy orders (including Canadian timing variability), making utilization, forecasting and CDMO capacity planning less predictable over the medium term.

Emergent Biosolutions Business Overview & Revenue Model

Company Description

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Emergent BioSolutions generates revenue through multiple streams, primarily by selling its vaccines and therapeutics to government agencies, including the U.S. Department of Health and Human Services and the Department of Defense, as well as international governments. The company's revenue model includes contract manufacturing services for third-party clients, which provides additional income through production capabilities. Significant partnerships, particularly with governmental organizations and large pharmaceutical companies, enhance its earnings by securing multi-year contracts and funding for research and development. Moreover, the company also benefits from grants and funding related to biodefense initiatives and public health preparedness programs.

Emergent Biosolutions Financial Statement Overview

Summary

Financials show a clear 2025 rebound (positive operating profit and $156.8M free cash flow), but the recovery follows several years of losses and continued revenue contraction. Leverage remains elevated (debt slightly above equity), which increases downside risk if profitability slips.

Income Statement

Results have been volatile. Revenue has contracted materially since 2021 (down to $742.9M in 2025 vs. $1.04B in 2024 and $1.77B in 2021), including a -5.8% decline in 2025. Profitability rebounded sharply in 2025 with positive operating profit ($100.1M) and net income ($52.6M) after deep losses in 2022–2024, and operating margin improved to ~19%. However, the lack of reported 2025 gross profit (0 value provided) limits visibility into core product economics, and the multi-year earnings swings remain a key concern.

Balance Sheet

Leverage is elevated and has worsened versus the pre-downturn period. Total debt is $572.1M against $522.6M of equity in 2025 (debt modestly above equity), though debt has come down from 2024–2022 levels. Returns on equity turned positive in 2025 (~10%) after meaningfully negative levels in 2022–2024, indicating improving profitability, but the capital structure still leaves less flexibility if earnings weaken again.

Cash Flow

Cash generation improved materially in 2025, with operating cash flow of $170.6M and free cash flow of $156.8M, a sharp turnaround from negative cash flow in 2022–2023 and modest levels in 2024. Cash flow quality also looks solid: free cash flow was close to reported net income in 2025 (about 0.9x). The main weakness is consistency—recent history includes periods of cash burn, suggesting execution and working-capital swings can meaningfully impact cash results.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	742.90M	1.04B	1.05B	1.12B	1.77B
Gross Profit	350.60M	375.40M	360.00M	473.00M	793.20M
EBITDA	237.90M	53.40M	-47.00M	15.70M	504.20M
Net Income	52.60M	-190.60M	-760.50M	-211.60M	219.50M
Balance Sheet
Total Assets	1.32B	1.39B	1.82B	3.17B	2.96B
Cash, Cash Equivalents and Short-Term Investments	205.40M	99.50M	111.70M	642.60M	576.30M
Total Debt	572.10M	676.10M	860.20M	1.43B	871.00M
Total Liabilities	796.00M	906.90M	1.17B	1.78B	1.35B
Stockholders Equity	522.60M	482.80M	649.30M	1.39B	1.61B
Cash Flow
Free Cash Flow	156.80M	35.80M	-257.90M	-149.90M	96.10M
Operating Cash Flow	170.60M	58.70M	-206.30M	-34.10M	321.10M
Investing Cash Flow	69.40M	125.20M	212.30M	-381.30M	-225.00M
Financing Cash Flow	-136.60M	-190.00M	-535.70M	481.20M	-141.00M

Emergent Biosolutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Negative. The current price of 8.44 is below the 20-day moving average (MA) of 10.49, below the 50-day MA of 11.52, and below the 200-day MA of 9.27, indicating a bearish trend. The MACD of -0.65 indicates Positive momentum. The RSI at 31.31 is Neutral, neither overbought nor oversold. The STOCH value of 29.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EBS.

Emergent Biosolutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	77 Outperform	$446.85M	-25.73	39.94%	―	-0.85%	-13.50%
PCRX	67 Neutral	$925.60M	163.97	0.96%	―	3.14%	―
ANIP	67 Neutral	$1.70B	14.40	15.11%	―	48.87%	―
AMPH	60 Neutral	$927.37M	12.76	12.90%	―	-0.03%	-27.66%
EBS	53 Neutral	$436.95M	12.57	10.46%	―	-29.91%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Emergent Biosolutions Corporate Events

Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts

Emergent BioSolutions Inc. announced on March 3, 2026, that it had appointed John D. Fowler, Jr. as a Class II independent director to its board effective March 1, 2026, with an initial term running through the 2026 annual shareholder meeting. Fowler will sit on the Audit and Finance Committee and receive standard non-employee director compensation, including cash retainers and equity grants vesting over three years.

The board highlighted Fowler’s more than three decades of leadership in healthcare and financial services, including senior roles at Wells Fargo Securities, Deutsche Bank, JPMorgan and Salomon Brothers, as well as experience leading and advising biotech firms. His appointment comes at what the company called an important phase in its turnaround and transformation, signaling a bid to strengthen financial oversight and strategic execution as Emergent seeks to drive long-term shareholder value and advance its public health mission.

The most recent analyst rating on (EBS) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround

On February 26, 2026, Emergent BioSolutions reported its fourth-quarter and full-year 2025 results, showing a sharp turnaround to full-year net income of $52.6 million from a $190.6 million loss in 2024, despite a 29% drop in revenue to $742.9 million. Profitability improved on higher gross and adjusted EBITDA margins, though the fourth quarter remained weak, with revenue down 24% to $148.7 million and a wider net loss of $54.6 million.

Management said the 2025 performance reflects progress on a multi-year turnaround, citing adjusted EBITDA of $205 million, stronger cash flow and reduced leverage. The company advanced its medical countermeasures franchise with over $450 million in contracts, maintained naloxone market leadership with more than $226 million in revenue, executed $24.8 million of share buybacks under a $50 million authorization, made a $100 million voluntary debt payment, completed asset sales, secured new naloxone rights, and prepared a fresh $50 million repurchase plan running from late February 2026 through March 2027.

The most recent analyst rating on (EBS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions outlines transformation and financial guidance at conference

On January 14, 2026, Emergent BioSolutions president and chief executive officer Joseph C. Papa presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining the company’s role in combating global public health threats and highlighting its diverse portfolio of biodefense and naloxone products. During the presentation, Emergent underscored its 2025 revenue guidance of $775 million to $835 million, emphasized recent progress in stabilizing and right‑sizing the business through divestitures, debt reduction and share and debt repurchases, and detailed a multi‑year transformation plan aimed at improving profitability, further deleveraging, and building synergistic verticals, developments that signal an effort to strengthen its financial position and long‑term value proposition for shareholders and government customers.

The most recent analyst rating on (EBS) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions Advances Turnaround With Major Debt Prepayment

Emergent BioSolutions announced on January 12, 2026, that it voluntarily prepaid $100 million of principal on its term loan facility in late December 2025 using cash on hand, a move the company framed as a key milestone in its multi‑year transformation and turnaround plan. With this payment, Emergent has reduced gross debt by $275 million since 2023 to about $593 million on a pro forma basis as of September 30, 2025, signaling improved financial flexibility and a stronger balance sheet for stakeholders as the company seeks long‑term stability and growth within the healthcare and biodefense sector.

The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions Gains FDA Approval for Winnipeg Facility

On December 12, 2025, Emergent BioSolutions announced that the U.S. FDA approved its Winnipeg, Canada facility for the manufacturing of raxibacumab, a monoclonal antibody for treating inhalational anthrax. This approval is part of Emergent’s multi-year transformation strategy to consolidate its manufacturing operations, supporting long-term growth and enhancing its manufacturing network. The Winnipeg facility, with over 45 years of experience, will play a crucial role in the company’s strategic manufacturing partnerships and operational focus.

The most recent analyst rating on (EBS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.